
1/34

# Formatted Alignments of AAV Genomes






FIG. 1A (cont'd)





FIG. 1A (cont'd)



6498 1 50

5/34




FIG. 1A (cont'd)




FIG. 1A (cont'd)




FIG. 1A (cont'd)




FIG. 1A (cont'd)




FIG. 1A (cont'd)




FIG. 1A (cont'd)




FIG. 1A (cont'd)




FIG. 1A (cont'd)




FIG. 1A (cont'd)




FIG. 1A (cont'd)





FIG. 1B



Problem Control

## 17/34

### Rep78






FIG. 3A

### VP1



TTC:-00



**BAAV** 

FIG. 3C

20/34




FIG. 3D




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B

26/34






Fig. 7



# Fig. 8



В

	IHC	OHC	VHC
BAAV	16%	28%	48%
AAV2	4.73%	0%	0%
AAV4	0%	0%	0%
AAV5	0%	0%	1%

Fig. 9




Fig. 10




Fig.11






Fig.12








Fig.15